Learning Objectives:
- Familiarize ourselves with the immune microenvironment in AML
- Appraise the major clinical studies evaluating immune checkpoint inhibitors (ICI) against the PD-1/PD-L1 axis, in the management of AML
- Identify key areas of unmet need in the study of immune checkpoint inhibitors in the management of AML
Session date:
09/29/2022 - 12:00pm to 1:00pm CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Athalia Pyzer, MD PhD